Memory Pharmaceuticals - wann geht uns das Licht auf? - 500 Beiträge pro Seite

[Hurli]

Es ist bislang sehr schwer, nähere Informationen über diese Aktie zu bekommen. Wie viele ihrer Artgenossen führt sie einen schönen Dornröschenschlaf und es ist nur schwer abzuschätzen, wohin der Weg, der bislang nur nach Süden ging, führt. Jetzt gab es mal wieder News bezüglich einer Milestone-Zahlung, die den Kurs etwas noch oben brachte. Ob dies einen Rebound hervorrufen wird, ist allerdings aufgrund der bisherigen Erfahrungen mit dieser Aktie fraglich.

Wer weiß mehr über diese Aktie und kann über den Erfolg und die Zeitschiene der Forschungsarbeiten etwas sagen? Aufgrund ihrer anspruchsvollen Forschungsziele (Alzheimer-Bekämpfung) hätte sie sicherlich etwas mehr Aufmerksamkeit in einem Thread verdient.

[WissenMacht]

[Hurli]

Antwort auf Beitrag Nr.: 26.683.274 von WissenMacht am 05.01.07 00:35:01

Der positive Newsfluss gegen Ende des alten Jahres scheint sich im Kurs des neuen Jahres niederzuschlagen. Wenn nun auch noch entsprechende Umsätze folgen, geht es wohl deutlich nach oben. Hast Du evtl. neue Fakten?

[URANI]

[URANI]

Antwort auf Beitrag Nr.: 26.909.104 von URANI am 14.01.07 14:18:24

[Hurli]

Antwort auf Beitrag Nr.: 26.911.252 von URANI am 14.01.07 15:29:27

Danke für die Info. Ich hoffe, der Chart hält was er verspricht. Sieht doch gut aus. Würde mich darüber hinaus auch freuen, wenn es bei der Behandlung von Alzheimer endlich mal Fortschritte geben würde. Viele leidvoll Betroffene wären unendlich dankbar.

[Hurli]

Die Chartentwicklung macht wirklich Spaß. Ich denke, wir werden an dem Papier noch viel Freude haben. Das dornenreiche Warten hat sich hier gelohnt.

[tenai]

Memory Pharmaceuticals to Present at Bio CEO & Investor Conference 2007

MONTVALE, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced that Jim Sulat, President and Chief Executive Officer, will provide a Company update at the Bio CEO&Investor Conference 2007 on Wednesday, February 14, 2007 at 12:45 p.m. ET, at the Waldorf=Astoria, New York City.

Interested parties may access a live audio webcast of the presentation by visiting the Investor Relations section of Memory Pharmaceuticals' website at http://www.memorypharma.com/. An archived version of the webcast will be available at the same location through Wednesday, February 21, 2007.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression and bipolar disorder. For additional information, please visit our website at http://www.memorypharma.com/.

[tenai]

Update Memory Pharmaceuticals Corp.: Buy

21.12.2006 15:48:03

Die Analysten von Lazard Capital Markets bewerten in ihrer Analyse vom Donnerstag, 21. Dezember 2006 die Aktie von Memory Pharmaceuticals Corp. neu mit dem Rating "Buy". Das Kursziel für die Aktie liegt momentan bei 4 $.


Quelle: Finanzen.net / Aktiencheck.de AG

[Hurli]

Antwort auf Beitrag Nr.: 27.529.031 von tenai am 08.02.07 22:05:01

Die 4 $ haben wir nun ja schon deutlich hinter uns gelassen. Ich denke, wir werden nächste Woche vielleicht schon 5 $ sehen. Der Chart gäbe das her.

[Hurli]

<< Back
Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results

MONTVALE, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system (CNS) conditions, today reported its financial results for the fourth quarter and year ended December 31, 2006.

"2006 was a significant year both clinically and strategically for Memory Pharmaceuticals. In addition to achieving multiple milestones under our collaborations, we also advanced our clinical pipeline with two ongoing Phase 2a trials. We also made important progress on the business front by expanding our nicotinic alpha-7 collaboration with Roche, and by strengthening our balance sheet," said Jim Sulat, President and Chief Executive Officer. "We anticipate that 2007 will bring additional significant clinical advances as we expect to complete by the end of the year proof-of-concept trials for MEM 1003 in bipolar disorder and Alzheimer's disease and for MEM 3454 in Alzheimer's disease."

For the quarter ended December 31, 2006, the Company reported a net loss of $14.7 million, or $0.23 per share, compared to a net loss of $3.6 million, or $0.10 per share, for the same period in 2005. Net loss for the quarter ended December 31, 2006 includes a non-cash loss of $6.0 million related to the warrants issued in the Company's September 2005 private placement and a non-cash charge of $0.5 million related to Statement of Financial Accounting Standards 123R, "Share-based Payments" (SFAS 123R). For the quarter ended December 30, 2006, after removing the effects of the two non-cash items noted above, the Company's non-GAAP net loss was $8.1 million, or $0.13 per share.

For the year ended December 31, 2006, the Company reported a net loss of $31.1 million, or $0.70 per share, compared to a net loss of $31.7 million, or $1.20 per share, in 2005. The 2006 net loss includes a non-cash loss of $0.2 million related to the warrants issued in the Company's September 2005 private placement and a non-cash charge of $2.6 million related to SFAS 123R. After removing the effects of the two non-cash items noted above, the Company's non-GAAP net loss for 2006 was $28.3 million, or $0.64 per share.

In calculating non-GAAP earnings, management excludes any unrealized gains or losses on the warrants issued in the Company's 2005 private placement and the expense associated with SFAS 123R. Current GAAP requires that the fair value of the warrants issued in the 2005 private placement be classified as a liability on the Company's Balance Sheet, with the change in fair value recognized in the Company's Statement of Operations as unrealized gains or losses. This treatment results from the potential magnitude for cash penalties if the Company fails to maintain the registration statement related to its 2005 private placement. A reconciliation of GAAP to non-GAAP earnings is presented in the tables at the end of this press release.

For the quarter ended December 31, 2006, the Company reported revenue of $2.6 million, compared to revenue of $3.7 million for the same period in 2005. For the year ended December 31, 2006, revenue was $9.3 million, compared to revenue of $11.1 million in 2005. Revenue relates to the Company's two agreements with Hoffmann La-Roche, one of which is for the development of PDE4 inhibitors and the other for the development of nicotinic alpha-7 agonists, and the Company's agreement with Amgen for the development of PDE10 inhibitors. This revenue includes the amortization of upfront non-refundable fees and milestone payments, in addition to payments received for research and development funding.

Research and development expenses for the quarter ended December 31, 2006 were $10.5 million compared to $8.2 million for the same period in 2005. The increase in operating cost included $3.2 million in increased costs associated with the clinical development of MEM 1003 and MEM 3454 and $0.1 million increased personnel and personnel-related costs. Included in the 2006 personnel and personnel-related costs is a $0.3 million non-cash compensation charge related to SFAS 123R. Research and development expenses for the quarter ended December 31, 2005 included a $1.0 million milestone payment to Bayer associated with the commencement of the Phase 2a clinical trial of MEM 1003 in November 2005.

Research and development expenses for the year ended December 31, 2006 were $33.8 million compared to $33.7 million for the same period in 2005. The increase in operating cost included $2.2 million in increased costs associated with the clinical development of MEM 1003 and MEM 3454 and a $0.1 million increase in insurance cost. These cost increases were partially offset by $0.9 million in reduced personnel and personnel-related costs, and $0.3 million in reduced laboratory supply costs. Personnel and personnel-related costs in 2006 include a $1.4 million non-cash compensation charge related to SFAS 123R. Research and development expenses for the year ended December 31, 2005 included a $1.0 million milestone payment to Bayer associated with the commencement of the Phase 2a clinical trial of MEM 1003 in November 2005.

General and administrative expenses for the quarter ended December 31, 2006 were $1.8 million, compared to $2.0 million for the same period in 2005. For the fourth quarter of 2006, these expenses include a $0.4 million reduction in legal and patent fees, offset by a $0.2 million increase in personnel and personnel-related costs. Included in the personnel and personnel related costs is a non-cash compensation charge of $0.2 million related to SFAS 123R.

General and administrative expenses for the year ended December 31, 2006 were $8.4 million compared to $8.4 million for the same period in 2005. For the year ended December 31, 2006, these expenses include a non-cash compensation charge of $1.2 million related to SFAS 123R that was offset by decreased legal and patent fees of $0.6 million, decreased personnel and personnel-related costs of $0.3 million and reduced administrative cost of $0.3 million.

At December 31, 2006, the Company had cash, cash equivalents and marketable securities of approximately $51.3 million, compared to $44.1 million at the end of 2005. The Company expects that its existing cash, cash equivalents, and marketable securities, together with payments required to be made under its collaboration agreements, should be sufficient to fund operating expenses, repayment of equipment notes, and capital equipment requirements through the middle of 2008.

Fourth Quarter Highlights and Recent Developments

--MEM 3454

Investigational new drug application (IND) approved for MEM 3454 for Alzheimer's disease. In December 2006, the Company announced that the U.S. Food and Drug Administration had released the clinical hold on MEM 3454 after completing its review of the IND for this drug candidate. The Company plans to start the Phase 2a trial of MEM 3454 in Alzheimer's disease in the first quarter of 2007.

Achieved Milestone for Development of MEM 3454 from Roche. In October 2006, the Company announced that Roche elected to maintain its option to obtain an exclusive license for MEM 3454, the lead compound from the Company's nicotinic alpha-7 receptor agonist alliance, triggering a milestone payment to the Company of $2.0 million. Roche's decision was based upon the Company's Phase 1 work on MEM 3454, which satisfied a set of criteria that was pre-defined by Roche.

--MEM 1003

Completed Dosing of Phase 2a Trial of MEM 1003 in Bipolar Disorder. In November 2006, the Company announced that it had completed enrollment in its Phase 2a trial of MEM 1003 in patients with acute mania in bipolar disorder, which the Company is conducting as part of its agreement with The Stanley Medical Research Institute (SMRI). The Company has now completed dosing patients in the trial and expects to report top-line results in the first quarter of 2007.

Achieved Milestone for Phase 2a Trial of MEM 1003 in Bipolar Disorder. In November 2006, the Company announced that it had earned a milestone payment of $960,000 from SMRI related to the ongoing Phase 2a trial of MEM 1003 in patients with acute mania in bipolar disorder. In January 2007, the Company earned its second milestone of $640,000 from SMRI related this trial. These milestone payments were triggered by a set of criteria, pre-defined by SMRI, regarding the progress of the trial.

-- Financial Position

Closed $32.2 Million Private Placement. In October and December 2006, the Company raised gross proceeds of approximately $32.2 million through a private placement of 28.2 million shares of common stock at $1.11 per share and warrants for the purchase of an aggregate of 7.1 million shares of common stock at an exercise price of $1.33 per share.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call on Thursday, February 22, 2007, at 9:00 a.m. EST to discuss the Company's fourth quarter and full year 2006 financial results. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Thursday, February 22, 2007
Time: 9:00 a.m. EST
Telephone (U.S.): 866.356.4281
Telephone (international): 617.597.5395
Participant Passcode: 11640389
Webcast: http://www.memorypharma.com under the
"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EST on Thursday, February 22, 2007, until Thursday, March 1, 2007. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 50028326. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression and bipolar disorder. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; conducting preclinical and clinical trials of Memory Pharmaceuticals' drug candidates that demonstrate these candidates' safety and effectiveness; receiving unfavorable results from clinical trials of Memory Pharmaceuticals' drug candidates; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationship with Bayer; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on third-party preclinical or clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward- looking statements as a result of developments occurring after the date of this press release.


MEMORY PHARMACEUTICALS CORP.
CONDENSED STATEMENTS OF OPERATIONS AND NON-GAAP ADJUSTMENTS
(in thousands - except share and per share information)
(unaudited)

Three Months Ended Year Ended
December 31, December 31,
2006 2005 2006 2005

Revenue $2,640 $3,705 $9,322 $11,116

Operating expenses:
Research and development 10,534 8,174 33,800 33,684
General and administrative 1,767 2,018 8,444 8,443
Total operating expenses 12,301 10,192 42,244 42,127
Loss from operations (9,661) (6,487) (32,922) (31,011)
Unrealized gain/(loss)
on warrants (6,048) 2,243 (247) (1,641)
Interest income, net 586 375 1,674 750
Loss before income taxes (15,323) (3,869) (31,695) (31,902)
Income tax benefit (396) (224) (388) (217)
Net loss attributable to
common stockholders $(14,727) $(3,645) $(31,107) $(31,685)
Basic and diluted net loss
per share of common stock $(0.23) $(0.10) $(0.70) $(1.20)
Basic and diluted weighted
average number of shares
of common stock
outstanding 63,831,072 37,417,068 44,334,129 26,350,193

Non-GAAP adjustments:

Net loss attributable
to common stockholders $(14,727) $(3,645) $(31,107) $(31,685)
Unrealized (gain)/loss
on warrants 6,048 (2,243) 247 1,641
Non-cash compensation
charge associated with
SFAS 123R 544 - 2,606 -
Non-GAAP net loss
attributable to common
stockholders(1) $(8,135) $(5,888) $(28,254) $(30,044)
Non-GAAP basic and diluted
net loss per share of
common stock(1) $(0.13) $(0.16) $ (0.64) $ (1.14)

(1) Excludes gains or losses on the warrants issued in the 2005 private
placement and the expense associated with SFAS 123R.


MEMORY PHARMACEUTICALS CORP.
CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)

December 31, December 31,
2006 2005
ASSETS
Cash, cash equivalents and marketable
securities $51,323 $44,079
Other current assets 1,397 2,562
Restricted cash 509 505
Property and equipment, net 7,413 9,167

Total assets $60,642 $56,313

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities (excluding deferred revenue) $7,664 $5,901
Warrant Liability 8,724 8,477

Equipment notes payable, less current portion 345 1,089

Deferred revenue 20,707 19,895

Total liabilities 37,440 35,362
Stockholders' equity 23,202 20,951

Total liabilities and stockholders' equity $60,642 $56,313

SOURCE Memory Pharmaceuticals Corp.
-0- 02/22/2007
/CONTACT: Jzaneen Lalani, General Counsel, [phone]; or Lilian
Stern of Stern Investor Relations, Inc. for Memory Pharmaceuticals Corp.,
[phone]/
/Web site: http://www.memorypharma.com /
(MEMY)

CO: Memory Pharmaceuticals Corp.
ST: New Jersey
IN: MTC HEA BIO
SU: ERN CCA

BR
-- NYTH041 --
9529 02/22/2007 06:30 EST http://www.prnewswire.com

Hom

[Hurli]

Hat jemand eine Erklärung dafür, wie heute in Frankfurt der Kurs mit 200 Stck. um über 10 % gedrückt werden konnte?

[Hurli]

Na super, heute über 23 % up bei gehandelten Kursen. Mal sehen, wie sich die Sache nächste Woche weiterentwickelt. Ich denke, da ist noch Luft nach oben drin. Ende diesen Anfang nächsten Jahres dürfte sich entscheiden, ob die klinischen Ergebnisse halten, was sie versprechen. Dann ist ein Kursvervielfacher drin.

[Peederwoogn2]

ob der boden gefunden ist?

[Hurli]

Antwort auf Beitrag Nr.: 29.089.271 von Peederwoogn2 am 02.05.07 08:44:53

Danke,dass sich mal wieder jemand in diesen Thread verirrt hat.

Ich denke, dieses Papier ist wie alle pharmazeutischen Forschungsunternehmen weniger nach Charts als nach News zu beurteilen, und davon müsste es dieses Jahr noch einige, wie's aussieht positive, geben. Das würde nicht nur unserem Kurs, sondern auch einer Vielzahl an Alzheimer-Patienten gut tun.

Warten wir mal in Ruhe die derzeit laufenden klinischen Tests ab.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.089.502 von Hurli am 02.05.07 09:06:14

ich hab gekauft weil mir der chart sehr gut gefällt.

[Hurli]

Antwort auf Beitrag Nr.: 29.111.395 von Peederwoogn2 am 03.05.07 13:33:32

Wenn man den erwarteten Newsstream dagegen stellt könntest Du sogar recht bekommen.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.111.395 von Peederwoogn2 am 03.05.07 13:33:32

sieht so aus als wenn es nur eine kurze korrektur wird

http://www.wallstreet-online.de/charts/instinformer.php?bgcolor=F1F1E7FE&&inst_id=10233&market_id=9&spid=ws&tr=3m&ct=jc&log=1&redvol=0&ind1=macd&ind2=rsi&gd1=100&gd2=200&&1178532151&volume=1

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.185.366 von Peederwoogn2 am 07.05.07 12:03:34

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.185.382 von Peederwoogn2 am 07.05.07 12:05:13

[Hurli]

Antwort auf Beitrag Nr.: 29.428.302 von Peederwoogn2 am 23.05.07 07:17:37

Mit deinen Charts könntest du richtig liegen. Die ausgeprägte W-Formation scheint die reale Kursentwicklung vorzugeben. Ich glaube, wir sind auf guten Wege.

[Peederwoogn2]

nächstes ziel ist das april hoch bei 3,22 $ dort sollte eine konselidirung un bedingt statt finden um kraft für ein neues altzeit hoch zu sammeln

[Hurli]

Antwort auf Beitrag Nr.: 29.496.709 von Peederwoogn2 am 28.05.07 10:58:07

Vielen Dank für Deine aussagekräftigen Charts. Heute RT 2,25 € erreicht. Viel fehlt nicht mehr.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.526.314 von Hurli am 29.05.07 16:35:05

da für nicht ich hab von pharmazeutischen forschungsunternehmen und bio unternehmen wenig plan kannst du da noch etwas beisteuern

gruß peederwoogn





sieht nach gewinn mit nahmen aus vielleicht auch nur weil wir sonst ein kleines gab hätten

nun bei knapp 80% kursgewinn im mai sollte eine korrektur nicht so un werscheinlich sein


ich hoff mal aufs gab

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.526.792 von Peederwoogn2 am 29.05.07 16:58:55

oh hatte ich fast vergessen im 5 tageschat ist schon ein gab.




2,65 $ sollten wir noch wiedersehen

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.527.572 von Peederwoogn2 am 29.05.07 17:45:19

die stärke der aktie ist schon erstaunlich.


ich hab mal den jahreschart mir genauer angeschaut, wenn ich nicht all zu sehr da neben liege sollten wir in den kommenden monaten ein neues altzeit hoch sehen.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.534.074 von Peederwoogn2 am 30.05.07 08:08:40

ich sicher meine position mit einen stop loss bei 2,69 $

[Peederwoogn2]

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.605.448 von Peederwoogn2 am 03.06.07 10:12:32

[Hurli]

Peederwoogn, was gibt's Neues zu MP? Dürfte man wieder News geben, die den Kurs nach oben bringen.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 31.002.079 von Hurli am 03.08.07 12:13:07

wer schön, wenn man das mit den news wüste


charttechnisch siehts nich so gut aus zur zeit nur auf WL


gruß peederwoogn

[Peederwoogn2]

bin wieder long drin durchschnitt 2,13 $

[Hurli]

Antwort auf Beitrag Nr.: 31.208.333 von Peederwoogn2 am 17.08.07 17:44:17

Mein Schnitt liegt immer noch bei 2,55 €. Dürfte aber auch kein Problem sein, wenn weitere positive News kommen, mit denen ich bis Jahresende noch rechne.

[Hurli]

Daumen drücken!

MONTVALE, New Jersey, 29. August 2007 /PRNewswire-FirstCall/ - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) verkündete heute das Dosieren des ersten Themas in der einzelnen steigenden (TRAURIGEN) Studie der Dosis seines Phase 1 klinischen Programms von R4996/MEM 63908, ein teilweiser Agonist des Nikotinempfängers alpha-7. Die Mittel, die auf diesem Empfänger fungieren, konnten in der Behandlung von Krankheit und von Schizophrenie Alzheimers, sowie andere psychiatrische und neurologische Störungen vorteilhaft sein.

„Wir werden aufgeregt, um R4996/MEM 63908 in klinische Studien vorzurücken und das Potential der Nikotinempfänger alpha-7 Agonists in den mehrfachen CNS Anzeigen weiter erforschen,“, sagte Stephen Murray, M.D., Ph.D., medizinischer hauptsächlichoffizier. „Zusammen mit unserem Partner Roche, haben wir eine führende Position in der Entwicklung der Nikotinempfänger alpha-7 Agonists errichtet, und die Zuführung von R4996/MEM 63908 in die Klinik reflektiert unseren anhaltenden Fortschritt mit unserem Nikotinprogramm des Agonist-Alpha-7.“

Die randomisierte, double-blind, Placebo-kontrollierte Studie wertet die Sicherheit, die Erträglichkeit und die Pharmacokinetics der steigenden Dosen von R4996/MEM 63908 in den gesunden Erwachsenmannesfreiwilligern aus. Die Studie wird in Montreal, Kanada unter einem klinischen Versuchsantrag geleitet, den Gedächtnis-pharmazeutische Produkte mit Gesundheit Kanada einordneten. Als Teil des Phase 1 klinischen Programms für R4996/MEM 63908, plant die Firma, eine Nahrungsmittelinteraktion Studie in den männlichen Freiwilligern des gesunden Erwachsenen und eine randomisierte, Placebo-kontrollierte Eindosenstudie im älteren Mann und Fraufreiwilliger zu leiten. Die Firma erwartet, die TRAURIGE Studie im ersten Viertel von 2008 durchzuführen.

R4996/MEM 63908 wird als Teil der Nikotinzusammenarbeit des Empfängers alpha-7 der Firma mit Roche entwickelt. Unter den Bezeichnungen des Gesellschaftsvertrags mit Roche, löst die Einführung des Phase 1 Versuches für R4996/MEM 63908 eine Zahlung des Meilensteines $2.0 Million von Roche aus.

Eine bessere Übersetzung vorschlagen
Wir danken für Ihren Vorschlag zu Google Übersetzer.
Ihren Vorschlag zur Verbesserung der Übersetzungsqualität werden wir in künftigen Aktualisierungen unseres Systems berücksichtigen. MONTVALE, New Jersey, 29. August 2007 /PRNewswire-FirstCall/ - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) verkündete heute das Dosieren des ersten Themas in der einzelnen steigenden (TRAURIGEN) Studie der Dosis seines Phase 1 klinischen Programms von R4996/MEM 63908, ein teilweiser Agonist des Nikotinempfängers alpha-7. Die Mittel, die auf diesem Empfänger fungieren, konnten in der Behandlung von Krankheit und von Schizophrenie Alzheimers, sowie andere psychiatrische und neurologische Störungen vorteilhaft sein. „Wir werden aufgeregt, um R4996/MEM 63908 in klinische Studien vorzurücken und das Potential der Nikotinempfänger alpha-7 Agonists in den mehrfachen CNS Anzeigen weiter erforschen,“, sagte Stephen Murray, M.D., Ph.D., medizinischer hauptsächlichoffizier. „Zusammen mit unserem Partner Roche, haben wir eine führende Position in der Entwicklung der Nikotinempfänger alpha-7 Agonists errichtet, und die Zuführung von R4996/MEM 63908 in die Klinik reflektiert unseren anhaltenden Fortschritt mit unserem Nikotinprogramm des Agonist-Alpha-7.“ Die randomisierte, double-blind, Placebo-kontrollierte Studie wertet die Sicherheit, die Erträglichkeit und die Pharmacokinetics der steigenden Dosen von R4996/MEM 63908 in den gesunden Erwachsenmannesfreiwilligern aus. Die Studie wird in Montreal, Kanada unter einem klinischen Versuchsantrag geleitet, den Gedächtnis-pharmazeutische Produkte mit Gesundheit Kanada einordneten. Als Teil des Phase 1 klinischen Programms für R4996/MEM 63908, plant die Firma, eine Nahrungsmittelinteraktion Studie in den männlichen Freiwilligern des gesunden Erwachsenen und eine randomisierte, Placebo-kontrollierte Eindosenstudie im älteren Mann und Fraufreiwilliger zu leiten. Die Firma erwartet, die TRAURIGE Studie im ersten Viertel von 2008 durchzuführen. R4996/MEM 63908 wird als Teil der Nikotinzusammenarbeit des Empfängers alpha-7 der Firma mit Roche entwickelt. Unter den Bezeichnungen des Gesellschaftsvertrags mit Roche, löst die Einführung des Phase 1 Versuches für R4996/MEM 63908 eine Zahlung des Meilensteines $2.0 Million von Roche aus.

(Google Übersetzung)

[Hurli]

Der klinische Phase 2a Test ist wohl nicht zu den gewünschten Ergebnissen gelangt. Das Ergebnis spiegelt sich im Kurs wieder.

Man kann nur hoffen, dass die Erkenntnisse aus diesem Test zu Verbesserungen führen, die sich in absehbarer Zeit in besseren Testergebnissen niederschlagen.

Hoffentlich hat der Kurs heute eine Boden gefunden. Für's Nachkaufen fehlt mir allerdings im Moment noch der Mut.

[Erbse1]

Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease
Friday November 2, 6:00 am ET
- Statistically Significant Improvement on Primary and Secondary Endpoints -
- Cognitive Benefits Support Further Development -
- Company to Host Conference Call Today at 9:00 a.m. EDT -


MONTVALE, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced positive top-line data from the randomized, placebo-controlled, multi-center Phase 2a proof-of-concept trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in 80 patients with mild to moderate Alzheimer's disease over an eight week treatment period. The trial was an exploratory efficacy study to learn about MEM 3454 as a potential treatment for Alzheimer's disease. The primary endpoint of the trial was the change from baseline in the Quality of Episodic Secondary Memory (QESM) factor score of the Cognitive Drug Research (CDR) battery. QESM is a composite score derived from memory tests in the CDR battery that measure the ability to store, hold and retrieve information. There were three oral daily doses of MEM 3454 tested in the trial, 5 mg, 15 mg and 50 mg. The CDR battery was administered at baseline and on six days during the treatment period, at four time points (pre-dosing and 2, 4 and 8 hours post-dosing) each day. For the eight hour post-dose time points over the treatment period, subjects receiving 5 mg and 15 mg of MEM 3454 demonstrated a statistically significant effect on the QESM compared to placebo (p=0.023 and p=0.050, respectively).
ADVERTISEMENT


Secondary endpoints in the trial included other composite scores from the CDR battery that measure working memory, attention and executive function, and the Alzheimer's Disease Assessment Scale -- cognitive subscale (ADAS-Cog). On secondary CDR battery measures, using all time points combined over the treatment period, the trial showed that the 5 mg and 15 mg doses achieved statistically significant positive results on Quality of Working Memory (p=0.031 and p=0.047). The 15 mg group also demonstrated trends to efficacy on Speed of Memory (p=0.080). Quality of Working Memory is a composite score derived from accuracy measures in the CDR battery that reflect how well subjects can hold information in working memory. The Speed of Memory composite score reflects the time it takes to recall an item from memory. For the ADAS-cog, the 15 mg group showed numeric improvements favoring treatment over placebo. There were two additional secondary endpoints in the study from the CDR battery, Power of Attention and Continuity of Attention, and on these measures the study found no statistically significant differences between treatment and placebo. The 50 mg group also showed no statistically significant differences favoring treatment at any endpoint in the study.

In analyses of QESM at certain other time points, and for all time points combined, the placebo group performed statistically significantly better than the treatment groups due to substantially lower QESM scores at baseline for the placebo group, at the 2 and 4-hour time points, as compared to the treatment groups. After adding a covariate for baseline scores to the statistical model, the MEM 3454 5 mg group demonstrated a statistically significant change from baseline on QESM at all time points combined compared to placebo (p=0.032). The MEM 3454 5 mg and 15 mg dose groups demonstrated statistical significance (p=0.003 and p=0.023, respectively), and the 50 mg dose group demonstrated a trend favoring treatment (p=0.083) for the eight hour post-dose time points on QESM. In addition, the 5 mg and 15 mg dose groups demonstrated a statistically significant effect on Quality of Working Memory, over all time points combined (p=0.006 and p=0.004, respectively). The 5 mg dose group also demonstrated a statistically significant effect on Speed of Memory (p<0.001) over all time points combined.

"Overall, the data from this study demonstrate that MEM 3454 is providing cognitive benefit and these results are consistent with our previous work with this compound in volunteers. When an appropriate baseline covariate is included, the results of this trial are even more robust," stated Keith Wesnes, Ph.D., the developer of the CDR battery. "It is exciting to improve the ability of Alzheimer's patients to store and retrieve information from both working and episodic memory, not only in terms of accuracy but also speed. These improvements have clinical relevance."

"We believe these trial results provide evidence of MEM 3454's potential to treat Alzheimer's disease," stated Stephen R. Murray, M.D., Ph.D., Chief Medical Officer of Memory Pharmaceuticals. "This data is consistent with our preclinical and Phase 1 results and reinforces our belief that MEM 3454 warrants continued development. We look forward to commencing our Phase 2a trial of MEM 3454 in cognitive impairment associated with schizophrenia in the near term."

MEM 3454 was well-tolerated in this trial, with the exception that the number of subjects with constipation was higher in the treatment groups (43%) compared to placebo (5%). There was one treatment-emergent serious adverse event in the 15 mg group, which was deemed not to be treatment-related by the investigator.

Study Design

The Phase 2a trial was a randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454. The trial enrolled 80 subjects with mild to moderate Alzheimer's disease at five sites in the United States. Subjects in the study were randomized at enrollment to receive 5 mg, 15 mg or 50 mg of MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial was to assess the effect of MEM 3454 using the QESM factor score from the CDR battery. Secondary objectives included assessing the safety, tolerability, and pharmacokinetics of MEM 3454 and the drug candidate's effect on additional psychometric test items from the CDR battery and the ADAS-cog.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 32.251.364 von Erbse1 am 02.11.07 11:08:18

damit hab ich nach den kurseinbruch nicht gerechnet

[Hurli]

Antwort auf Beitrag Nr.: 32.251.364 von Erbse1 am 02.11.07 11:08:18

Na wer sagt's denn. Das gibt doch wieder Hoffnung auf einen Kurs Richtung N. Ich bleibe long und erwarte einen guten Ausgang der Testserien.

[sub-seven]

Kursziel 1,75$

[Peederwoogn2]

Antwort auf Beitrag Nr.: 32.252.555 von sub-seven am 02.11.07 12:05:08

ja da iss noch ein gab

[cyberhai]

Pre-Market: 1.63 Up 0.70 (75.27%) as of 8:18AM ET on 11/02/07

[Hurli]

Wenn ich das richtig verstanden habe, hat Memory jetzt die Aufforderung der NASDAQ erhalten, innerhalb von 8 Monaten eine 1 vor das Komma zu bringen, sonst droht Delisting. Um dies zu vermeiden, wird wohl ein Aktiensplitt bevorstehen, es sei denn, es gibt innerhalb dieser Frist gute News und der Kurs geht kräftig nach N, was mir bedeutend lieber wäre. Aber ich glaube, darauf müssen wir noch geraume Zeit warten.

[Hurli]

Antwort auf Beitrag Nr.: 32.693.037 von Hurli am 07.12.07 09:20:49

Der bisherige CEO Jim Sulat wurde durch einen von den Hauptanteilseignern auf 6 Monate eingesetzten Interims-CEO Kailian abgelöst. Ein neuer CEO soll gesucht werden.

Sulat soll aus persönlich-familiären Gründen zurückgetreten sein und künftig in Teilzeit als CFO tätig sein.

Weiß jemand, was dahinter steckt bzw. was der Grund war?

[YabbaDabbaDoo]

Press Release
Source: Memory Pharmaceuticals Corp.

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
Friday May 2, 6:05 am ET
-Memory Receives $6 Million Milestone Payment-
-Memory to Host Conference Call at 9:00 a.m. EDT Today-

MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) and Roche (SWX: ROG - News) today announced that Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders. Roche's exercise of its option for MEM 3454 triggers a $6 million milestone payment and entitles Memory Pharmaceuticals to future payments upon the achievement of additional milestones and royalties on product sales, including a $17 million milestone payment upon the completion of the ongoing Phase 2a study in cognitive impairment associated with schizophrenia (CIAS). In addition, Memory Pharmaceuticals retains an option to co-promote MEM 3454 in the United States.

ADVERTISEMENT
"We are excited that Roche shares our enthusiasm for MEM 3454 and its potential to address the cognitive deficits associated with debilitating CNS disorders," stated Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "We have aggressively advanced MEM 3454 through early-stage clinical trials, including a positive Phase 2a trial in Alzheimer's disease. We believe that Roche's continued commitment to the program, together with its expertise in later-stage clinical development and commercialization, will provide the support and capabilities to realize the full potential of this compound."

In a recently completed Phase 2a study in Alzheimer's disease patients, MEM 3454 demonstrated a statistically significant effect on multiple measures of cognition. The compound is currently being evaluated in a Phase 2a trial in CIAS, with top-line results expected in the fourth quarter of 2008. The trial is expected to enroll approximately 160 patients and is designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454 in patients with CIAS. In addition, Memory Pharmaceuticals and Roche recently expanded their schizophrenia development program for MEM 3454 to include a biomarker study, which will be funded by Roche. Memory Pharmaceuticals expects to initiate the biomarker trial this summer, with results expected by early 2009.

MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system. Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders.

Conference Call Information

Memory Pharmaceuticals will hold a conference call today, May 2, 2008 at 9:00 a.m. EDT to discuss this announcement. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Friday, May 2, 2008
Time: 9:00 a.m. EDT
Telephone (U.S.): 866.314.4483
Telephone (international): 617.213.8049
Participant Passcode: 38691567
Webcast: http://www.memorypharma.com under the
"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Friday, May 2, 2008, until Friday, May 9, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 95627100. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About Memory Pharmaceuticals

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

http://biz.yahoo.com/prnews/080502/nyf032.html?.v=101
Source: Memory Pharmaceuticals Corp.

[YabbaDabbaDoo]

What the Roche $$$ means 2-May-08 12:39 pm
For MEMY $23,000,000 means the ability to survive an additional 12 months.

Tey imply that royalties will be forthcoming sometime by the endof next year.

Thiscan only sbe assumed to be as a part of a combo treatments of which 3454 is a component.

This also lays the groundwork for other molecules to be pulled off the shelf and partnered by other large pharmas.

They live to fight another year and that allows them to get more deals and more financing - and maybe even arrange to repurchase and reissue the locked up shares in a more positive maner - some convertibles perhaps isued at a strike price at +$1 and also the org that has the obligation to purchase more shaers will also be triggered to buy if the stock achieves a higher level for an extended periodof time....they still live and breather but they need more to get back to where the stock was a short 12 months ago...

[YabbaDabbaDoo]

I don't post much....... 2-May-08 01:31 pm
but I've been long MEMY for a long time now and I think those who scalped & sold today or those longs that bailed will be very, very sorry...look at a previous post on this board today..big pharma needs these biotechs and will be buying them up and partnering with them...but that's just one reason..to those that remain long & strong ..congrats the reward will come !!!!!!!!!!GL all

Piney Woods...

http://messages.finance.yahoo.com/mb/MEMY

[YabbaDabbaDoo]

Form 10-Q for MEMORY PHARMACEUTICALS CORP

15-May-2008

Quarterly Report


Item 2.
Management's Discussion and Analysis of Financial Condition and Resultsof Operations

This Management's Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information to help you better understand and evaluate our financial condition and results of operations. We recommend that you read this section in conjunction with our financial statements and notes to financial statements in Item 1 and with our Annual Report on Form 10-K for the year ended December 31, 2007.
Some of the statements contained in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. We generally identify these statements by words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," "should," "estimate," "predict," "potential," "continue," or the negative of such terms or other similar expressions. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. Factors that might cause such a difference include those discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, and below in Part II, Item 1A. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.
OVERVIEW
Since our incorporation in March 1997, we have devoted substantially all of our resources to the discovery and development of innovative drug candidates for the treatment of a broad range of CNS conditions, many of which exhibit significant impairment of memory and other cognitive functions. These conditions include neurological diseases associated with aging, such as Alzheimer's disease, and also include certain psychiatric disorders such as schizophrenia.

Table of Contents

Our drug development pipeline currently includes five programs, nicotinic alpha-7 agonists, PDE4 inhibitors, PDE10 inhibitors, 5-HT6 antagonists and an L-type calcium channel modulator. We seek to leverage our pipeline of early development candidates through collaborations with leading pharmaceutical and biotechnology companies. We have a collaboration with Roche for the development of nicotinic alpha-7 agonists and a collaboration with Amgen for the development of PDE10 inhibitors. We are currently funding three programs on our own.
• Nicotinic Alpha-7 Agonist Program

Our nicotinic alpha-7 receptor program is being conducted pursuant to a collaboration with Roche, which we entered into in August 2003 and subsequently amended and restated in February 2006 (the "Amended and Restated 2003 Roche Nicotinic Alpha-7 Agonist Agreement"). Under the terms of the Amended and Restated 2003 Roche Nicotinic Alpha-7 Agonist Agreement, we granted to Roche a worldwide, exclusive, sublicensable license to all of our patent rights and know-how with respect to our nicotinic alpha-7 agonists, other than R3487/MEM 3454, for the prevention and treatment of diseases, in all indications, for either human or veterinary use. In May 2008, Roche exercised its license option to R3487/MEM 3454, which will result in a $6.0 million milestone payment to us in the second quarter of 2008.

We have collaborated with Roche in conducting certain early stage research and development activities with respect to compounds being developed under this agreement, and we are responsible for conducting Phase 1 clinical trials for such compounds. Roche is responsible for clinical development from Phase 2a onwards and for commercialization of such compounds. We are eligible to receive milestone payments upon our achievement of specified development, regulatory and commercialization milestones (including sales level milestones) for compounds that are developed under the agreement.

R3487/MEM 3454, a partial agonist of the nicotinic alpha-7 receptor, is the lead candidate from our nicotinic alpha-7 agonist program and is being developed for the treatment of Alzheimer's disease and cognitive impairment associated with schizophrenia. In November 2007, we announced positive top-line data from a Phase 2a trial that evaluated the safety and efficacy of R3487/MEM 3454 in patients with mild to moderate Alzheimer's disease. R3487/MEM 3454 demonstrated a statistically significant effect on cognition at the 5 milligram and 15 milligram doses on both the primary and key secondary endpoints for that trial.

In June 2007, we further amended the Amended and Restated 2003 Roche Nicotinic Alpha-7 Agonist Agreement to, among other changes, provide that we would conduct and pay for a Phase 2a clinical trial of R3487/MEM 3454 in CIAS, which we refer to as the R3487/MEM 3454 Phase 2a CIAS clinical trial. In December 2007, we commenced the R3487/MEM 3454 Phase 2a CIAS clinical trial. Roche is obligated to make a $17.0 million milestone payment to us upon the completion of the R3487/MEM 3454 Phase 2a CIAS clinical trial.

The R3487/MEM 3454 Phase 2a CIAS clinical trial is being funded in part through our stock purchase agreement with SMRI and The Sylvan C. Herman Foundation, pursuant to which we have agreed to sell up to an aggregate of $6.0 million of our common stock in three equal tranches. We refer to this as our 2007 Private Placement. The first tranche of the 2007 Private Placement closed in June 2007. Upon our achievement of predefined milestones related to the R3487/MEM 3454 Phase 2a CIAS clinical trial and subject to the satisfaction of certain closing conditions (including provisions that we have no current intention of terminating the trial and that we are in compliance with requirements for continued listing on Nasdaq), we have the option, in our sole discretion, to sell to SMRI and The Sylvan C. Herman Foundation an aggregate of $4.0 million of common stock in two tranches of $2.0 million each, at a 17% premium to the market price at the time the milestone is achieved.

In February 2008, we announced plans to conduct a study of R3487/MEM 3454 on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia. The primary objective of the trial is to study P50 sensory gating and mismatch negativity as potential efficacy biomarkers for nicotinic alpha-7 agonists, such as R3487/MEM 3454, in schizophrenia. External costs of the biomarker study will be funded by Roche under the Amended and Restated 2003 Nicotinic Alpha-7 Agonist Agreement.

R4996/MEM 63908 is the second drug candidate to be nominated from our nicotinic alpha-7 agonist program and is also a partial agonist of the nicotinic alpha-7 receptor. We commenced a Phase 1 program for R4996/MEM 63908 in August 2007 under a Clinical Trial Application that we filed with Health Canada. We have completed the single ascending dose study portion of the program and are currently conducting studies investigating the effect of food on pharmacokinetic

properties and the effect of age and gender on pharmacokinetic properties and tolerability and a multiple ascending dose study.
Through March 31, 2008, Roche has paid us a total of $36.3 million under this collaboration, comprised of an upfront license fee of $10.0 million, research and development funding of $10.3 million, milestone payments of $6.0 million and an equity investment of $10.0 million.
• PDE4 Inhibitor Program

In July 2002, we entered into a collaboration with Roche for the development of PDE4 inhibitors. During the course of this collaboration, we named two drug candidates, MEM 1414, which has completed Phase 1 clinical trials, and MEM 1917. In June 2007, we restructured the 2002 Roche PDE4 Inhibitor Agreement to reacquire from Roche all rights to the PDE4 inhibitor program. We are currently evaluating alternatives for the further development of our PDE4 inhibitor program, which could include taking the program forward, in whole or in part, on our own or with a new collaboration partner. We plan to progress MEM 1414 into a Phase 2a trial by the end of 2008. Through June 2007, when we entered into the Amended and Restated 2002 Roche PDE4 Inhibitor Agreement, Roche paid us a total of $26.0 million in connection with our PDE4 inhibitor program, comprised of an upfront license fee of $8.0 million, research and development funding of $14.0 million and milestone payments totaling $4.0 million. Under certain circumstances, we are obligated to make milestone payments to Roche in the future.
• PDE10 Inhibitor Program

In October 2005, we entered into a collaboration with Amgen for the development of PDE10 inhibitors for neurological and psychiatric disorders, pursuant to which we conducted a two-year collaborative preclinical research program relating to PDE10 inhibitors in accordance with a predefined research work plan. Under the terms of the 2005 Amgen PDE10 Inhibitor Agreement, Amgen is obligated to make milestone payments to us upon the achievement of pre-specified research, development, regulatory approval and sales milestones relating to PDE10 inhibitors. Amgen has paid us a total of $14.2 million through March 31, 2008 comprised of a $5.0 million upfront fee, $7.2 million in research and development funding and a $2.0 million milestone payment. In February 2008, the 2005 Amgen PDE10 Inhibitor Agreement was amended to extend our commitment to the preclinical research portion of the collaboration. In connection with the amendment, we agreed to commit and fund certain preclinical research resources and provide Amgen increased access to our screening technologies through February 2009. In exchange, we will receive increased milestone payments upon the achievement of certain predefined development events for the program. In addition, the amendment expanded the scope of compounds eligible for higher tier royalties under the agreement. We have the right to terminate the extension of the research portion of the collaboration upon four weeks' notice, in which case the amendment will terminate and the terms of the original agreement will be reinstated.
• 5-HT6 Antagonist Program

We have internally developed a portfolio of novel, potent and selective 5-HT6antagonists, which includes compounds that are covered by intellectual property that we licensed from NPS Allelix Corp., or NPS, in October 2003 under a license agreement which we amended and restated in April 2007. We refer to this as our Amended and Restated 2003 NPS 5-HT6 Antagonist Agreement. We are evaluating several lead compounds from this portfolio as potential development candidates and plan to advance this program into clinical trials by the end of 2008. Under the terms of the Amended and Restated 2003 NPS 5-HT6 Antagonist Agreement, we have an exclusive, sub-licensable license under certain NPS patents and know-how to 5-HT6 antagonists for the treatment of diseases, in all indications, for either human or veterinary use. We are required to make payments to NPS upon our achievement of specified development and regulatory milestones.
• L-Type Calcium Channel Modulator

MEM 1003 is a neuronal L-type calcium channel modulator that we are developing for the treatment of Alzheimer's disease. In October 2007, we reported top-line results from a Phase 2a study that evaluated the safety and efficacy of MEM 1003 in patients with mild to moderate Alzheimer's disease. The trial failed to meet its primary endpoint, which was the twelve-week mean change in the Alzheimer's disease Assessment Scale-Cognitive subscale ("ADAS-cog") score in the overall population. Based on these results, we have determined that any further development of MEM 1003 would require our securing a collaboration partner for this program.

In March 2007, we announced that we had completed a Phase 2a trial of MEM 1003 in bipolar mania and that MEM 1003 did not prove effective in that trial. We have completed a full analysis of the data from that trial and do not, at this time, have plans to proceed with further clinical trials of MEM 1003 in bipolar disorder. We conducted the MEM 1003 Phase 2a bipolar disorder clinical trial with funding support from SMRI in the aggregate amount of $3.2 million. Under the agreement with SMRI, we received $1.0 million of this funding in exchange for the issuance of 440,367 shares of our common stock and a warrant to purchase 154,128 shares of our common stock at an exercise price of $2.62 per share that expires on December 19, 2010. We received the remaining $2.2 million of funding in the form of milestone payments.
We have an exclusive worldwide, sub-licensable license to MEM 1003 from Bayer AG, or Bayer, for the treatment of human peripheral and CNS-related disorders. As of December 31, 2007, we had paid $2.0 million in upfront and milestone payments to Bayer under this agreement. We are required to make additional payments to Bayer of up to $18.0 million in the event that we achieve specified milestones and to pay royalties on sales of any products incorporating MEM 1003. Since our inception, we have incurred substantial losses, and as of March 31, 2008, we had an accumulated deficit of $230.1 million, of which $19.5 million related to preferred stock dividends that were forfeited upon the conversion of our redeemable convertible preferred stock upon the closing of our initial public offering on April 8, 2004. These losses and accumulated deficit have resulted from the significant costs incurred in the research and development of our compounds and technologies, including payroll and payroll-related costs, manufacturing costs of preclinical and clinical grade materials, facility and facility-related costs, preclinical study costs, clinical trial costs, and general and administrative costs. We are funding or contemplating funding the development of several of our drug candidates and programs. Our most significant commitment currently is to R3487/MEM 3454, for which we are funding the R3487/MEM 3454 Phase 2a CIAS clinical trial, which began in December 2007. We believe that our existing cash and cash equivalents, and marketable securities, together with payments expected to be made by our collaboration partners will be sufficient to fund our operating expenses, repayment of equipment notes, scheduled obligations under our loan from Hercules Technology Growth Capital, Inc. ("Hercules") and capital equipment requirements into the first half of 2009.
We have financed our operations since inception through the sale of equity securities, payments received under our collaboration and development agreements, equipment financings, interest income and, most recently, through debt financing.
Since our inception, we have raised gross proceeds totaling $190.8 million through the sale of our equity securities. In September 2005, we raised gross proceeds of $31.0 million in a private placement, issuing 16,112,158 shares of common stock, at a price of $1.90 per share, and warrants to purchase an aggregate of 5,639,232 shares of common stock at an exercise price of $2.22 per share. We refer to this as our 2005 Private Placement. In October and December 2006, we closed a two-tranche private placement, raising gross proceeds of $32.2 million and issuing an aggregate of 28,232,202 shares of our common stock at a purchase price of $1.11 per share and warrants to purchase 7,058,042 shares of our common stock at an exercise price of $1.33 per share. We refer to this as our 2006 Private Placement. In February 2007, we exercised our right to require the exercise of the October 2006 warrants pursuant to their terms, resulting in gross proceeds to us of $5.0 million and the issuance of an aggregate of 5,402,593 additional shares of common stock. In connection with the 2007 Private Placement, we have raised gross proceeds to date of $2.0 million, issuing an aggregate of 694,444 shares of common stock at a price of $2.88 per share.
In March 2007, we entered into a $10.0 million term loan agreement with Hercules (the "Hercules Loan Agreement"), which was amended in June 2007 to increase the maximum loan amount to $15.0 million. As of March 31, 2008, we have borrowed the full amount under the Hercules Loan Agreement. We are required to make interest-only payments on a monthly basis through May 2008, and any amounts outstanding at that time are required to be repaid in 30 equal monthly installments of principal and interest beginning in June 2008. In connection with the Hercules Loan Agreement and the Hercules Amendment, we issued to Hercules warrants to purchase 598,086 and 325,521 shares of our common stock at exercise prices of $2.09 and $1.92 per share, respectively.
CRITICAL ACCOUNTING POLICIES
Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, accrued expenses, research and development, the fair value of our equity securities, the valuation of the Hercules put option, and the likelihood that an event or circumstance that constitutes a material adverse effect under the terms of the Hercules

Loan Agreement will occur. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies affect the judgments and estimates used in the preparation of our financial statements. Use of estimates
The preparation of the financial statements requires us to make a number of estimates and assumptions relating to the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Significant items subject to such estimates and assumptions include the fair value of our equity securities, carrying amount of property, plant and equipment, valuation allowances for deferred income tax assets, the estimated development period of compounds under our collaborations for revenue recognition purposes and estimated liabilities for services provided in connection with our clinical programs. Actual results could differ from those estimated. Revenue recognition
We recognize revenue from our research collaborations in accordance with the SEC's Staff Accounting Bulletin (SAB) No. 104, Revenue Recognition, and other such pronouncements as are applicable, and with EITF Issue No. 00-21, Accounting for Revenue Arrangements with Multiple Deliverables (EITF No. 00-21), which is applicable and effective for revenue arrangements entered into in fiscal periods beginning after June 15, 2003.
Revenue arrangements with multiple deliverables are reviewed in order to determine whether the multiple elements can be divided into separate units of accounting. If separable, the consideration received is allocated among the separate units of accounting based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units. Otherwise, the applicable revenue recognition criteria are applied to combined elements as a single unit of accounting. Revenues under such collaborations include the receipt of non-refundable license fees, milestone payments and research and development funding. Revenues from research collaboration agreements considered as separate units are recognized as and when the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection is reasonably assured. Combined elements including upfront payments for the use of technology, where further services are to be provided or fees received on the signing of research agreements, are recognized over the period of performance of the related activities. Amounts received in advance of recognition of revenue are reported as unearned, or deferred, revenues, as are amounts which are refundable if underlying conditions are not met.
We have determined that each of our collaboration agreements with multiple deliverables will be accounted for under a "single unit contract model" that is based on the terms of the collaborations and deliverables. Accordingly, upfront license fees, milestone payments and research and development funding received under our collaboration agreements is deferred and recognized over the term of our substantive contractual obligations.
We are recognizing the non-refundable upfront license fees, milestone payments, and research and development funding received under the Amended and Restated 2003 Roche Nicotinic Alpha-7 Agonist Agreement and the remaining deferred revenue from the Amended and Restated 2002 Roche PDE4 Inhibitor Agreement as a single unit of accounting over the estimated period of our continuing performance obligations with respect to the first compound to be developed thereunder. Solely for purposes of revenue recognition under the Amended and Restated 2003 Roche Nicotinic Alpha-7 Agonist Agreement, we have estimated the relevant period of our continuing performance obligations as ending in the fourth quarter of 2013. In previous periods the estimate of the end of the relevant period of our continuing performance obligations under this agreement had been the third quarter of 2013.
We periodically review the estimated development periods and our estimated research efforts under our collaborations and, to the extent such estimates change, the impact of such change is recorded prospectively. Payments received from our collaboration partners for research and development activities performed by us that are deemed to be a separate unit of accounting, as defined by EITF No. 00-21, are recognized as revenue as research and development services are performed. Otherwise, the payments are recognized as revenue over the term of the applicable collaboration agreement or the expected period for the first compound to be developed under the agreement.

Accrued expenses
As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for such service where we have not been invoiced or otherwise notified of actual cost. This is done as of each balance sheet date in our financial statements. Examples of estimated accrued expenses include:
• professional service fees, such as attorneys' and accountants' fees;

• preclinical and clinical contract research organization fees;

• fees to be paid to data management organizations and investigators in conjunction with clinical trials; and

• fees to be paid to contract manufacturers in conjunction with the production of the supply of our drug candidates for preclinical and clinical trials.

In connection with the above services, our estimates are most affected by our projections of the timing of services provided relative to the actual level of services performed by such service providers. The majority of our service providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs that have begun to be incurred or we under- or over-estimate the level of services performed or the costs of such services, our actual expenses could materially differ from such estimates. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services are often subjective determinations. We make these judgments based upon the facts and circumstances known to us in accordance with US GAAP.
Research and development expense
Research and development expense consists primarily of costs associated with our internal research and development activities, including salaries, and related expenses for personnel, stock based compensation, costs of facilities and equipment, fees paid to contract research organizations and consultants in connection with our preclinical studies and clinical trials, including for services such as the independent monitoring of our clinical trials and the evaluation of data from our clinical trials, costs of materials used in research and development, upfront and milestone payments under our in-licensing agreement, consulting, license and sponsored university-based research fees paid to third parties, and depreciation of capital assets used to develop our drug candidates.
Stock-based payment arrangements
Effective January 1, 2006, we began recording compensation expense associated with stock options and other forms of equity compensation in accordance with SFAS No. 123R. Prior to January 1, 2006, we accounted for stock options according to the provisions of Accounting Principles Board (APB) Opinion 25, Accounting for Stock Issued to Employees, and related interpretations, and therefore, no related compensation expense was recorded for awards granted to employees and members of our Board of Directors with no intrinsic value. We adopted the modified prospective transition method provided for under SFAS No. 123R, and consequently, we have not retroactively adjusted results from prior periods. Under this transition method, compensation cost associated with stock options recognized includes: (i) amortization related to the remaining unvested portion of all stock option awards granted prior to January 1, 2006, based on the grant-date fair value estimated in accordance with the original provisions of SFAS No. 123; and (ii) amortization related to all stock option awards granted on or subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS No. 123R. We apply the provisions of EITF Issue No. 96-18, Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services(EITF No. 96-18), to our non-employee stock-based awards. Under EITF No. 96-18, the measurement date at which the fair value of the stock-based award is measured is equal to the earlier of (1) the date at which a commitment for performance by the non-employee to earn the equity instrument is reached or (2) the date at which the non-employee's performance is complete. We recognize stock-based compensation expense for the fair value of the awards in our statements of operations. Application of EITF No. 96-18 requires us to measure the fair value of the awards as of each reporting date up to and including the final vesting date. During the three months ended March 31, 2008, we issued stock options to purchase 130,000 shares of common stock to non-employees.



Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
Friday May 16, 12:00 pm ET

MONTVALE, N.J., May 16 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. In addition, the Company has nominated MEM 68626 as the lead development candidate from its 5-HT6 antagonist program, and separately confirmed its 2008 development goals for its pipeline.

"We are extremely excited about the progress we have made in advancing our programs," said Vaughn M. Kailian, President and Chief Executive Officer of Memory Pharmaceuticals. "MEM 1414 produced a robust CNS signal in a human quantitative EEG study. In addition, using human whole blood assays, we have identified plasma concentrations required for anti-inflammatory activity. These data, combined with previous pharmacokinetic and safety data obtained in Phase 1 clinical trials for MEM 1414, will guide dosing for a proof-of-concept trial in either a cognition or respiratory indication, which we expect to initiate by the end of 2008."

Mr. Kailian continued, "Further, we are pleased to report that we have nominated MEM 68626 as the lead compound in our 5-HT6 antagonist program. MEM 68626 has demonstrated strong preclinical efficacy data in cognition and has a favorable safety and pharmacokinetic profile, which we believe offers advantages over other compounds in development. We look forward to advancing MEM 68626 into the clinic this year."

MEM 1414 - Potential in Cognition and Inflammation

Memory Pharmaceuticals reported the results of a clinical study of MEM 1414 on quantitative EEG (qEEG), a biomarker of central nervous system (CNS) activity. The randomized, double-blind, placebo-controlled, cross-over study enrolled twelve healthy volunteers and evaluated three doses of MEM 1414 (250, 500 and 750 mg). In the study, the 500 and 750 mg doses produced a statistically significant increase in both the absolute and relative power of the EEG signal in the alpha frequency. In addition, the 250 mg dose produced a strong trend on certain electrodes. Effects were consistent with previous preclinical data and with the pharmacokinetic profile of MEM 1414, and supplement the preclinical data in models of inflammation. In these models, MEM 1414 demonstrated robust anti-inflammatory effects and suppressed cytokine release from human whole blood. Together, this data package supports both pro-cognitive and anti-inflammatory indications and provides guidance for dosing in future clinical trials.

MEM 68626 - Lead 5-HT6 Antagonist

MEM 68626 was nominated as the lead development candidate in the Company's 5-HT6 antagonist program. MEM 68626 is a novel, potent and selective antagonist of the 5-HT6 receptor, a validated target for the treatment of cognitive disorders. The compound has demonstrated efficacy in multiple preclinical models of cognition and obesity and has a favorable safety and toxicology profile in in vivo studies, with no cardiovascular or genetic toxicity issues. In addition, MEM 68626 has superior pharmaceutical-like properties and the compound's pharmacokinetic profile suggests the potential for once-daily, oral dosing.

2008 Program Goals
The Company confirmed its development goals for 2008:
-- Initiate a biomarker study for R3487/MEM 3454 this summer, with results
expected by early 2009
-- Complete and report top-line results for its Phase 2a trial of
R3487/MEM 3454 in cognitive impairment associated with schizophrenia
(CIAS) in the fourth quarter
-- Complete and report top-line results for its Phase 1 program of
R4996/MEM 63908 in the fourth quarter
-- Initiate a Phase 2a trial for MEM 1414 by year-end
-- Initiate a Phase 1 trial for MEM 68626 by year-end.


About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals' ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


Source: Memory Pharmaceuticals Corp.

[YabbaDabbaDoo]

Heute 356822 Stück an der NasdaqGM : MEMY
d.h. doppeltes Durchschnittsvolumen (154219)
bei steigendem Kurs...0.43 - 0.51 Tagesrange
Last Trade 0,48 ( 9.07% )

[YabbaDabbaDoo]

[YabbaDabbaDoo]

Antwort auf Beitrag Nr.: 32.693.037 von Hurli am 07.12.07 09:20:49

Hi Hurli

Alles wird gut
und wenn sie weiterhin so kaufen
braucht es bald keinen Splitt mehr

Beste Grüsse

[YabbaDabbaDoo]

Last Trade 0,66

Volume 1.230083

Trading Range 0,50 - 0,66


Bis zum Dollar fehlen nur noch 44 Cent

[Peederwoogn2]

da is aber was los

[URANI]

Antwort auf Beitrag Nr.: 34.145.095 von Peederwoogn2 am 21.05.08 18:38:15

Habe mir mal ne kleine Posi zu 0,36 Euro geholt ! Mal schauen was passiert..... is aber ne menge Bewegung drin...

[URANI]

Memory Pharmaceuticals Development-Pipeline

[URANI]

Antwort auf Beitrag Nr.: 34.145.925 von URANI am 21.05.08 20:11:04

[URANI]

[URANI]

Mann oh mann ich bin echt zu blöde......

[Hurli]

Die neuen Meldungen von der klinischen Erprobung klingen vielversprechend. Ich denke, das wird dem Kurs wieder auf die Beine helfen. Bis Jahresende sollten wir meines Erachtens Verdoppelungspotential haben.

Bitte weiteres unter:
http://phx.corporate-ir.net/phoenix.zhtml?c=175500&p=irol-ne…" target="_blank" rel="nofollow ugc noopener">http://phx.corporate-ir.net/phoenix.zhtml?c=175500&p=irol-ne…

[Peederwoogn2]

http://app.quotemedia.com/quotetools/newsStory.go?storyId=12…


sieht nicht gut aus

[gerdass]

Montvale (aktiencheck.de AG) - Das US-Biotechnologieunternehmen Memory Pharmaceuticals Corp. (ISIN US58606R4039 / WKN A0B9N6) hat einer Übernahmeofferte des schweizerischen Pharmariesen Roche Holding AG (ISIN CH0012032113 / WKN 851311) zugestimmt.




Wie aus einer am Dienstag veröffentlichten Pressemitteilung des US-Konzerns hervorgeht, habe man sich auf die Übernahme durch den Schweizer Pharmakonzern geeinigt. Im Rahmen der Übernahmeofferte sollen die Anteilseigner von Memory Pharmaceuticals 0,61 Dollar je Aktie erhalten, was einem Aufschlag von 319 Prozent gegenüber dem letzten Schlusskurs der Aktie entspricht. Das Gesamtvolumen der Übernahmeofferte beläuft sich auf 50 Mio. Dollar.

Memory Pharmaceuticals ist auf die Entwicklung von Medikamenten zur Behandlung von Erkrankung des zentralen Nervensystems wie etwa Alzheimer oder Schizophrenie spezialisiert.

Die Aktie von Memory Pharmaceuticals notierte zuletzt bei 0,15 Dollar.
(25.11.2008/ac/n/a)


Quelle: Finanzen.net / Aktiencheck.de AG

© Aktiencheck.de AG

[Hurli]

Antwort auf Beitrag Nr.: 36.063.589 von gerdass am 25.11.08 19:13:42

Roche würde wohl zu diesem Kurs nicht übernehmen wollen, wenn die Erfolgsaussichten nicht interessant wären.

Soll man nun das Angebot annehmen oder die weitere Entwicklung abwarten. Ich neige zu letzterem. Was meint ihr?